N-Acetylcysteine supplementation for the prevention of atrial fibrillation after cardiac surgery: a meta-analysis of eight randomized controlled trials

• Published in: BMC cardiovascular disorders 2012-02, Vol.12 (1), p.10-10, Article 10
• Main Authors: Gu, Wan-Jie, Wu, Zhen-Jie, Wang, Peng-Fei, Aung, Lynn Htet Htet, Yin, Rui-Xing
• Format: Article
• Language: English
• Subjects: Acetylcysteine - therapeutic use; Aged; Aged, 80 and over; Antioxidants; Atrial Fibrillation - etiology; Atrial Fibrillation - prevention & control; Cardiac Surgical Procedures; Clinical trials; Female; Free Radical Scavengers - therapeutic use; Heart attacks; Heart surgery; Hospital costs; Hospitalization; Human subjects; Humans; Male; Meta-analysis; Middle Aged; Oxidative stress; Postoperative Complications - prevention & control; Prospective Studies; Randomized Controlled Trials as Topic; Sensitivity analysis; Studies; Veins & arteries
• ISSN: 1471-2261; 1471-2261
• DOI: 10.1186/1471-2261-12-10

Atrial fibrillation is the most common type of arrhythmia after cardiac surgery. An increasing body of evidence demonstrates that oxidative stress plays a pivotal role in the pathophysiology of atrial fibrillation. N-acetylcysteine (NAC) is a free radical scavenger, and may attenuate this pathophysiologic response and reduce the incidence of postoperative AF (POAF). However, it is unclear whether NAC could effectively prevent POAF. Therefore, this meta-analysis aims to assess the efficacy of NAC supplementation on the prevention of POAF. Medline and Embase were systematically reviewed for studies published up to November 2011, in which NAC was compared with controls for adult patients undergoing cardiac surgery. Outcome measures comprised the incidence of POAF and hospital length of stay (LOS). The meta-analysis was performed with the fixed-effect model or random-effect model according to the heterogeneity. Eight randomized trials incorporating 578 patients provided the best evidence and were included in this meta-analysis. NAC supplementation significantly reduced the incidence of POAF (OR 0.62, 95% CI 0.41 to 0.93; P = 0.021) compared with controls, but had no effect on LOS (WMD -0.07, 95% CI -0.42 to 0.28; P = 0.703). The prophylactic NAC supplementation may effectively reduce the incidence of POAF. However, the overall quality of current studies is poor and further research should focus on adequately powered randomized controlled trials with POAF incidence as a primary outcome measure.